AASLD guidelines for treatment of chronic hepatitis B

doi:10.1002/HEP.28156

Home
/
Papers
/
AASLD guidelines for treatment of chronic hepatitis B

Journal Article•DOI•

AASLD guidelines for treatment of chronic hepatitis B

Norah A. Terrault¹, Natalie Bzowej², Kyong-Mi Chang³, Jessica P. Hwang⁴, Maureen M. Jonas⁵, M. Hassan Murad⁶ - Show less +2 more•Institutions (6)

University of California, San Francisco¹, Ochsner Medical Center², University of Pennsylvania³, University of Texas at Austin⁴, Harvard University⁵, Mayo Clinic⁶

01 Jan 2016-Hepatology (John Wiley and Sons Ltd)-Vol. 63, Iss: 1, pp 261-283

TL;DR: Aasld Guidelines for Treatment of Chronic Hepatitis B Norah Terrault;Natalie Bzowej;Kyong-Mi Chang;Jessica Hwang;Maureen Jonas;Hassan Murad; Hepatology

read less

About: This article is published in Hepatology.The article was published on 2016-01-01 and is currently open access. It has received 1596 citations till now. The article focuses on the topics: Hepatitis B & Hepatology.

...read moreread less

Citations

PDF

Open Access

More filters

Journal Article•DOI•

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

[...]

Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L.A. Janssen, George V. Papatheodoridis, Fabien Zoulim¹, Frank Tacke - Show less +4 more•Institutions (1)

HCL Technologies¹

01 Aug 2017-Journal of Hepatology

TL;DR: This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection, and future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.

...read moreread less

3,016 citations

Cites background or methods from "AASLD guidelines for treatment of c..."

...Patient selection according to disease activity, HBV genotype, stage of the disease, as well as levels of HBV DNA, HBsAg and HBeAg status can be helpful indicators to predict the individual response probability.(1,56) Early ontreatment predictors are established and can be used as additional tools (e....
[...]
...At present, patients co-infected by HBV and HDV have to be treated with PegIFNa....
[...]
..., ETV, TDF, TAF) is its predictable high long-term antiviral efficacy leading to undetectable HBV DNA levels in the vast majority of compliant patients as well as its favourable safety profile (Table 2).(1,56,57) These drugs can be safely used in any HBV infected patient and represent the only treatment option for several patient subgroups including those with decompensated liver disease, liver transplants, extrahepatic manifestations, acute hepatitis B or severe chronic HBV exacerbation....
[...]
...In addition, preventing HBV transmission in patients with high viremia who do not fulfill the typical criteria for treatment initiation represents further indications in which only NAs should be used.(1,49,50,52,56,57) The rationale for a PegIFNa based approach is to induce longterm immunological control with a finite duration treatment....
[...]
...In HBeAg-negative CHB patients under NA treatment, two multicentre European studies have assessed the safety and efficacy of a 48-week add-on course of PegIFNa.139,140 These two studies demonstrated that HBsAg kinetics were fostered by the addition of PegIFNa, but only a few patients cleared HBsAg....
[...]

Journal Article•DOI•

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

[...]

Norah A. Terrault¹, Anna S. Lok², Brian J. McMahon, Kyong-Mi Chang³, Jessica P. Hwang⁴, Maureen M. Jonas, Robert S. Brown⁵, Natalie Bzowej⁶, John B. Wong⁷ - Show less +5 more•Institutions (7)

University of California, San Francisco¹, University of Michigan², University of Pennsylvania³, University of Texas at Austin⁴, Cornell University⁵, Ochsner Medical Center⁶, Tufts University⁷

01 Apr 2018-Hepatology

TL;DR: This AASLD 2018 Hepatitis B Guidance provides a data-supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B.

...read moreread less

2,399 citations

Journal Article•DOI•

Approved Antiviral Drugs over the Past 50 Years

[...]

Erik De Clercq¹, Guangdi Li², Guangdi Li¹•Institutions (2)

Rega Institute for Medical Research¹, Central South University²

01 Jul 2016-Clinical Microbiology Reviews

TL;DR: This paper presents for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.

...read moreread less

Abstract: Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox). Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.

...read moreread less

985 citations

Journal Article•DOI•

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

[...]

Thomas Karlas, David Petroff¹, Magali Sasso, Jian-Gao Fan², Yu Qiang Mi, Victor de Ledinghen, Manoj Kumar, Monica Lupsor-Platon³, Kwang Hyub Han⁴, Ana Carolina Cardoso⁵, Giovanna Ferraioli⁶, Wah-Kheong Chan⁷, Vincent Wai-Sun Wong⁸, Robert P. Myers⁹, Kazuaki Chayama¹⁰, Mireen Friedrich-Rust¹¹, Michel Beaugrand, Feng Shen², Jean Baptiste Hiriart, Shiv Kumar Sarin, Radu Badea³, Kyu Sik Jung⁴, Patrick Marcellin⁵, Carlo Filice⁶, Sanjiv Mahadeva⁷, Grace Lai-Hung Wong⁸, Pam Crotty⁹, Keiichi Masaki¹⁰, Joerg Bojunga¹¹, Pierre Bedossa¹², Volker Keim, Johannes Wiegand - Show less +28 more•Institutions (12)

Leipzig University¹, Shanghai Jiao Tong University², Iuliu Hațieganu University of Medicine and Pharmacy³, Yonsei University⁴, University of Paris⁵, University of Pavia⁶, University of Malaya⁷, The Chinese University of Hong Kong⁸, University of Calgary⁹, Hiroshima University¹⁰, Goethe University Frankfurt¹¹, Paris Diderot University¹²

01 May 2017-Journal of Hepatology

TL;DR: CAP provides a standardized non-invasive measure of hepatic steatosis and factors such as the underlying disease, BMI and diabetes must be taken into account when interpreting CAP.

...read moreread less

641 citations

Cites background from "AASLD guidelines for treatment of c..."

...[4] Terrault NA, Bzowej NH, Chang K, Hwang JP, Jonas MM, Murad MH....
[...]

Journal Article•DOI•

Shared and Distinct Functions of Type I and Type III Interferons.

[...]

Helen M. Lazear¹, John W. Schoggins², Michael S. Diamond³•Institutions (3)

University of North Carolina at Chapel Hill¹, University of Texas Southwestern Medical Center², Washington University in St. Louis³

16 Apr 2019-Immunity

TL;DR: A model wherein type III IFNs serve as a front-line defense that controls infection at epithelial barriers while minimizing damaging inflammatory responses, reserving the more potent type I IFN response for when local responses are insufficient is discussed.

...read moreread less

608 citations

Cites background from "AASLD guidelines for treatment of c..."

...…inhibited growth of several different tumor cell lines and diminished local and metastatic tumor formation in mice including cancers from lung, liver, breast, and prostate (Abushahba et al., 2010; Lasfar et al., 2016; Li et al., 2008; Numasaki et al., 2007; Sato et al., 2006; Tezuka et al., 2012)....
[...]

1
2
3
4
…
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200

Collapse

References

PDF

Open Access

More filters

Journal Article•DOI•

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

[...]

Rafael Lozano¹, Mohsen Naghavi¹, Kyle J Foreman², Stephen S Lim¹ +192 more•Institutions (95)

15 Dec 2012-The Lancet

TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex, using the Cause of Death Ensemble model.

...read moreread less

11,809 citations

Journal Article•DOI•

Grading quality of evidence and strength of recommendations.

[...]

David C. Atkins, Dana Best, Peter A. Briss, Martin P Eccles, Yngve Falck-Ytter, Signe Flottorp, Gordon H. Guyatt, Robin Harbour, Margaret C Haugh, David Henry, Suzanne Hill, Roman Jaeschke, Gillian Leng, Alessandro Liberati, Nicola Magrini, James Mason, Philippa Middleton, Jacek Mrukowicz, Dianne L. O'Connell, Andrew D Oxman, Bob Phillips, Holger J. Schünemann, Tessa Tan-Torres Edejer, H. Varonen, Gunn Elisabeth Vist, John W Williams, Stephanie Zaza - Show less +23 more

19 Jun 2004-BMJ

TL;DR: A system for grading the quality of evidence and the strength of recommendations that can be applied across a wide range of interventions and contexts is developed, and a summary of the approach from the perspective of a guideline user is presented.

...read moreread less

Abstract: Users of clinical practice guidelines and other recommendations need to know how much confidence they can place in the recommendations Systematic and explicit methods of making judgments can reduce errors and improve communication We have developed a system for grading the quality of evidence and the strength of recommendations that can be applied across a wide range of interventions and contexts In this article we present a summary of our approach from the perspective of a guideline user Judgments about the strength of a recommendation require consideration of the balance between benefits and harms, the quality of the evidence, translation of the evidence into specific circumstances, and the certainty of the baseline risk It is also important to consider costs (resource utilisation) before making a recommendation Inconsistencies among systems for grading the quality of evidence and the strength of recommendations reduce their potential to facilitate critical appraisal and improve communication of these judgments Our system for guiding these complex judgments balances the need for simplicity with the need for full and transparent consideration of all important issues

...read moreread less

7,608 citations

"AASLD guidelines for treatment of c..." refers methods in this paper

...Unlike previous AASLD practice guidelines, this guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.(1) Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline....
[...]
...summaries following the GRADE approach (Table 7).(1) In this approach, the quality of evidence (i....
[...]

Journal Article•DOI•

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

[...]

Chien-Jen Chen¹, Hwai I. Yang, Jun Su², C.-L. Jen¹, San Lin You¹, Sheng-Nan Lu³, Guan-Tarn Huang¹, Uchenna H. Iloeje² - Show less +4 more•Institutions (3)

National Taiwan University¹, Bristol-Myers Squibb², Chang Gung University³

04 Jan 2006-JAMA

TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.

...read moreread less

Abstract: ContextSerum hepatitis B virus (HBV) DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic hepatitis B.ObjectiveTo evaluate the relationship between serum HBV DNA level and risk of hepatocellular carcinoma.Design, Setting, and ParticipantsProspective cohort study of 3653 participants (aged 30-65 years), who were seropositive for the hepatitis B surface antigen and seronegative for antibodies against the hepatitis C virus, recruited to a community-based cancer screening program in Taiwan between 1991 and 1992.Main Outcome MeasureIncidence of hepatocellular carcinoma during follow-up examination and by data linkage with the national cancer registry and the death certification systems.ResultsThere were 164 incident cases of hepatocellular carcinoma and 346 deaths during a mean follow-up of 11.4 years and 41 779 person-years of follow-up. The incidence of hepatocellular carcinoma increased with serum HBV DNA level at study entry in a dose-response relationship ranging from 108 per 100 000 person-years for an HBV DNA level of less than 300 copies/mL to 1152 per 100 000 person-years for an HBV DNA level of 1 million copies/mL or greater. The corresponding cumulative incidence rates of hepatocellular carcinoma were 1.3% and 14.9%, respectively. The biological gradient of hepatocellular carcinoma by serum HBV DNA levels remained significant (P<.001) after adjustment for sex, age, cigarette smoking, alcohol consumption, serostatus for the hepatitis B e antigen (HBeAg), serum alanine aminotransferase level, and liver cirrhosis at study entry. The dose-response relationship was most prominent for participants who were seronegative for HBeAg with normal serum alanine aminotransferase levels and no liver cirrhosis at study entry. Participants with persistent elevation of serum HBV DNA level during follow-up had the highest hepatocellular carcinoma risk.ConclusionElevated serum HBV DNA level (≥10 000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.

...read moreread less

2,853 citations

Journal Article•DOI•

Chronic hepatitis B: Update 2009

[...]

Anna S.F. Lok¹, Brian J. McMahon²•Institutions (2)

University of Michigan¹, Alaska Native Medical Center²

01 Sep 2009-Hepatology

TL;DR: The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B is now posted online at www.aasld.org, and the recommendation for first-line oral antiviral medications has been changed to tenofovir or entecavir, and adefovir has been moved to second-line Oral antiviral medication.

...read moreread less

2,696 citations

Journal Article•DOI•

Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

[...]

Giovanna Fattovich¹, Tommaso Stroffolini, Irene Zagni¹, Francesco Donato²•Institutions (2)

University of Verona¹, University of Brescia²

01 Nov 2004-Gastroenterology

TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.

...read moreread less

2,248 citations